TY - JOUR
T1 - Arginine vasopressin receptor antagonists (vaptans)
T2 - Pharmacological tools and potential therapeutic agents
AU - Veeraveedu, Punniyakoti T.
AU - Palaniyandi, Suresh S.
AU - Yamaguchi, Ken'ichi
AU - Komai, Yutaka
AU - Thandavarayan, Rajarajan A.
AU - Sukumaran, Vijayakumar
AU - Watanabe, Kenichi
N1 - Funding Information:
This research was supported by a Yujin Memorial Grant from The Ministry of Education, Culture, Sports, Science, and Technology, Japan, and by a grant from the Promotion and Mutual Aid Corporation for Private Schools, Japan.
PY - 2010/10
Y1 - 2010/10
N2 - The development of various non-peptide vasopressin receptor antagonists presents a new area of drug discovery for the treatment of heart failure and hyponatremia of multiple causes. Arginine vasopressin (AVP) attracted attention as a potentially important neurohormonal mediator of the heart failure (HF) syndrome and hyponatremic states in humans because AVP influences renal handling of free water, vasoconstriction and myocyte biology through activation of V2 and V1a receptors. Current research is exploring V2- and dual V1a/V2 receptor antagonism for the treatment of hyponatremia, as well as for the congestion and edema associated with chronic HF, because vasopressin receptor antagonists might offer benefits in comparison with conventional loop diuretics. The purpose of this review is to update the current status of experimental and clinical studies with available vasopressin receptor antagonists (conivaptan and tolvaptan) and their potential role in the treatment of HF and hyponatremia of multiple causes.
AB - The development of various non-peptide vasopressin receptor antagonists presents a new area of drug discovery for the treatment of heart failure and hyponatremia of multiple causes. Arginine vasopressin (AVP) attracted attention as a potentially important neurohormonal mediator of the heart failure (HF) syndrome and hyponatremic states in humans because AVP influences renal handling of free water, vasoconstriction and myocyte biology through activation of V2 and V1a receptors. Current research is exploring V2- and dual V1a/V2 receptor antagonism for the treatment of hyponatremia, as well as for the congestion and edema associated with chronic HF, because vasopressin receptor antagonists might offer benefits in comparison with conventional loop diuretics. The purpose of this review is to update the current status of experimental and clinical studies with available vasopressin receptor antagonists (conivaptan and tolvaptan) and their potential role in the treatment of HF and hyponatremia of multiple causes.
UR - http://www.scopus.com/inward/record.url?scp=77957671658&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957671658&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2010.08.001
DO - 10.1016/j.drudis.2010.08.001
M3 - Review article
C2 - 20708094
AN - SCOPUS:77957671658
SN - 1359-6446
VL - 15
SP - 826
EP - 841
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 19-20
ER -